CYPHERPUNK TECHNOLOGIES INC. Fair Value Adjustment of Warrants
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Fair Value Adjustment of Warrants of $12.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2025-03-26
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2023-12-31 was $24.00K.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2023-09-30 was -$24.00K.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2023-06-30 was -$38.00K.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2023-03-31 was -$50.00K.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2023 was $12.00K.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2018 was -$7.28M.
- CYPHERPUNK TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2017 was -$473.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | -$38.00K derived: sum of 3 quarters · filed 2025-03-26 | $12.00K 10-K · filed 2025-03-26 | ||
| 2023-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$62.00K derived: sum of 2 quarters · filed 2024-11-13 | -$12.00K 10-Q · filed 2024-11-13 | $12.00K 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | -$38.00K 10-Q · filed 2023-08-14 | $12.00K 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | -$50.00K 10-Q · filed 2024-08-12 | $50.00K 10-Q · filed 2023-05-15 | ||||
| 2018-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$12.80M derived: sum of 2 quarters · filed 2020-03-16 | -$12.13M derived: sum of 3 quarters · filed 2020-03-16 | -$7.28M 10-K · filed 2020-03-16 | ||
| 2018-09-30 | -$1.79M 10-Q · filed 2019-11-14 | -$1.13M derived: sum of 2 quarters · filed 2019-11-14 | $3.72M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $662.00K 10-Q · filed 2019-08-09 | $5.51M 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | $4.85M 10-Q · filed 2019-05-15 | |||||
| 2017-12-31 | -$473.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |